Epitranscriptomic Regulation of Tumor Growth and Immune Evasion

92 concepts72 papers1 proposal

While the genetic code provides the blueprint for life, a hidden layer of chemical modifications on RNA—the epitranscriptome—determines how that blueprint is executed. In the context of oncology, researchers have discovered that cancer cells hijack these RNA modifications to stabilize oncogenic messages, rewire metabolism, and hide from the immune system. By modulating "writers" (enzymes that add modifications), "readers" (proteins that interpret them), and "erasers" (enzymes that remove them), tumors create a dynamic regulatory landscape that drives progression and therapeutic resistance.

The Epitranscriptomic Switch

The most prevalent internal modification in eukaryotic mRNA is $N^6$-methyladenosine ($m^6A$), but the epitranscriptome includes a diverse array of marks such as $N^1$-methyladenosine ($m^1A$), 5-methylcytosine ($m^5C$), $N^7$-methylguanosine ($m^7G$), and $N^4$-acetylcytidine ($ac4C$). As Guifang Jia notes in New Edges of RNA Adenosine Methylation Modifications, these modifications are highly dynamic and serve as critical regulators of translation and splicing.

In cancer, this system often malfunctions. For instance, the $m^6A$ writer METTL3 frequently acts as an oncogenic "gas pedal." Xu et al. demonstrate that METTL3 adds $m^6A$ tags to the mRNA of the tumor suppressor LATS1, signaling for its degradation via the reader YTHDF2. This effectively silences the Hippo signaling pathway, revving up tumor growth and glycolysis. Similar axes have been identified across various cancers: Yu et al. found a METTL3/YTHDF2/NR4A1 axis in cervical cancer, while Liu et al. identified a METTL3-m6A-CRB3-Hippo circuit in colorectal carcinoma.

Stabilizing the Oncogenic Message

Beyond $m^6A$, other modifications like $ac4C$ play specialized roles in stabilizing transcripts that fuel malignancy. The enzyme NAT10 acts as an $ac4C$ writer, chemically tagging mRNAs to increase their half-life. Yue and Hu show that NAT10 stabilizes DDIAS mRNA, activating the PI3K-Akt pathway to drive hepatocellular carcinoma.

This stabilization mechanism is a recurring theme in drug and radiation resistance. Zhou et al. describe a "vicious cycle" in lung cancer where $m^6A$ modifications protect survival-linked transcripts from radiation-induced damage. Similarly, Han et al. found that the reader IGF2BP2 stabilizes the long non-coding RNA DANCR, leading to chemoresistance in glioblastoma.

RNA-Mediated Immune Evasion

Perhaps the most significant clinical implication of epitranscriptomics is its role in "cold" tumor microenvironments. Tumors use RNA modifications to adjust their visibility to the immune system, effectively creating an epigenetic checkpoint.

Gong et al. argue that non-coding RNAs act as upstream regulators of immune checkpoints like PD-L1, influencing mRNA stability to help tumors evade T-cell attacks. This is not limited to non-coding sequences; Chen et al. show that the writer NAT10 stabilizes mRNAs involved in immune signaling, creating an immunosuppressive environment in pancreatic cancer. Crucially, the authors found that inhibiting NAT10 can "flip the switch," re-sensitizing these tumors to immunotherapy.

The relationship between the epitranscriptome and the immune landscape is so consistent that researchers are using modification signatures as biomarkers. Ding and Wu developed a prognostic model for Acute Myeloid Leukemia based on $m^5C$ regulators, while Gan et al. identified a "Psi Score" based on pseudouridine ($\Psi$) modifications that predicts how well colorectal cancer patients will respond to PD-L1 blockade.

Tuning the Ribosomal Machinery

While most research focuses on messenger RNA, the epitranscriptome also extends to the translation machinery itself. L. L. Liu et al. discovered that the enzyme METTL5 modifies the 18S ribosomal RNA. This modification "tunes" the ribosome to more efficiently translate specific cell-cycle regulators like CCND3, accelerating tumor growth in oral squamous cell carcinoma. This suggests that cancer cells do not just change which messages are sent; they upgrade the "factory" to prioritize oncogenic production.

By mapping these specific molecular axes—such as the METTL1-m7G-VEGFA axis in angiogenesis identified by Zhao et al.—researchers are moving toward a new era of precision oncology. Targeting the enzymes that write, read, and erase these RNA tags offers a way to disrupt the fundamental mechanisms that tumors use to survive, adapt, and hide.

Key Foundational Work

Characterization of RNA editome in primary and metastatic lung adenocarcinomas (2016) — contributed 1 concept elements to this direction.
New Edges of RNA Adenosine Methylation Modifications (2016) — contributed 1 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_epigenetic_checkpoint_modulation_d88556d4,
  title = {epigenetic checkpoint modulation},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/epigenetic-checkpoint-modulation/rdr_d88556d481bb4e11b1592dc37ba4fca7},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}

This exact version (version 1, frozen text):

@misc{lacuna_epigenetic_checkpoint_modulation_d88556d4_v1,
  title = {epigenetic checkpoint modulation},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/epigenetic-checkpoint-modulation/rdr_d88556d481bb4e11b1592dc37ba4fca7/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake